SceneRay

Suzhou, ChinaFounded 200911–50 employeessceneray.comLinkedIn

SceneRay is a medical device company dedicated to the design, Development, and distribution of neuromodulation devices.

Visit sceneray.com ↗

Founded: 2009
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

SceneRay’s most significant documented milestone remains its Series D financing announced on Feb 16, 2022, which raised approximately $47.3 million and brought cumulative funding to about $66.4 million. The round listed HSG as lead investor, while the company’s Apr 21, 2021 Series D financing was led by Yanchuang Capital; the repeated Series D designation and missing amount for the 2021 transaction are a point of financial-record uncertainty. SceneRay’s intellectual-property activity has centered on neuromodulation and surgical systems. Patent-related filings dated Mar 16, 2022 covered brain electrical-signal transmission and pre-operative nerve-stimulator placement screening, while filings dated Aug 8, 2022 and Aug 19, 2022 addressed implantable medical leads, pathway planning, and surgical systems. The company is credited with 110 granted patents and 23 registered trademarks. Publicly visible company-specific announcements after 2022 are limited. Hiring signals indicate continued recruitment for social and campus roles supporting brain-science research and operations, and there is no reported recent layoff activity.

Market position

SceneRay operates in medical devices with a focused specialization in implantable neuromodulation, particularly deep brain stimulation. Its product range spans the SR1101 rechargeable implantable neurostimulator, the Aaxon ND dual-channel implantable pulse generator, implantable leads and extensions, the TouchLoc Lead Fixture, and a clinician programmer. This gives the company exposure across several components of a DBS treatment system rather than a single implantable module. SceneRay’s stated differentiation is technical depth in neuromodulation design, manufacturing, and commercialization, supported by an intellectual-property portfolio that includes 110 granted patents and 23 registered trademarks. The company has raised approximately $66.4 million across three recorded rounds, including a $47.3 million Series D in 2022, indicating meaningful private-market backing for a medical-device business. The clearest evidence of market position is its broad DBS system portfolio, patent activity, and progression to Series D financing.

Growth & opportunities

SceneRay’s trajectory shows a progression from its 2009 founding toward a capital-backed neuromodulation platform with multiple DBS products. The company raised approximately $19.1 million in a Series C announced on Aug 1, 2017, followed by two transactions labeled Series D in 2021 and 2022. The latest dated round, announced on Feb 16, 2022, contributed approximately $47.3 million and brought recorded cumulative funding to $66.4 million. That financing scale, combined with a product portfolio covering generators, leads, extensions, fixation hardware, and clinician programming, suggests expansion beyond a single device into an integrated treatment ecosystem. Patent activity in 2022 provides evidence of continued engineering investment in implantable leads, surgical planning, brain-signal transmission, and implantation-position screening. The company is also associated with 110 granted patents and 23 registered trademarks. Current workforce information places SceneRay in the 11-50 employee range, while hiring for social and campus positions indicates ongoing efforts to support research and operations. Accordingly, the evidence supports sustained R&D and product breadth, but not a precise assessment of commercial acceleration through 2026.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Technology & products6

SR1101 Rechargeable Implantable Neurostimulator Kit for DBS
An implantable rechargeable neurostimulator designed for deep brain stimulation therapy, featuring dual-channel stimulation and long battery life.
Dual-channel Implantable Pulse Generator Kit for DBS (Aaxon ND)
An implantable dual-channel pulse generator for delivering electrical pulses in deep brain stimulation therapy.
Implantable Lead Kit for DBS
A set of implantable electrodes used to deliver electrical stimulation to specific brain regions in DBS therapy.
Implantable Extension Kit for DBS
An implantable extension cable set that connects the implanted neurostimulator to the brain electrodes in DBS systems.
TouchLoc® Lead Fixture
A device used to secure implanted brain electrodes in place during DBS procedures.
Clinician Programmer
A device used by clinicians to program and adjust implanted neurostimulators for DBS therapy.

Show all 6 products

+ 3 more: Implantable Extension Kit for DBS, TouchLoc® Lead Fixture, Clinician Programmer

About SceneRay

Products: SR1101 Rechargeable Implantable Neurostimulator Kit for DBS, Dual-channel Implantable Pulse Generator Kit for DBS (Aaxon ND), Implantable Lead Kit for DBS, Implantable Extension Kit for DBS, TouchLoc® Lead Fixture, Clinician Programmer
Leadership: Yihua Ning, General Manager
Focus areas: NeuroTechnology, medical device, neuromodulation, deep brain stimulation, health care
Headquarters: Suzhou, China
Founded: 2009
Employees: 11–50
Patents granted: 110 (Crunchbase)
Trademarks: 23